TrialCancer immunology, immunotherapy : CII2022

Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study.

Jin-Ji Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.